News

Colesevelam, an oral bile acid sequestrant for hypercholesterolemia, is developed by Genzyme and marketed in the US by Daiichi Sankyo under the brand name WelChol and elsewhere by

TMC278 is Tibotec Pharmaceuticals’ investigational non-nucleoside reverse transcriptase inhibitor for HIV-1 infection in adults. Gilead previously submitted an NDA for the single-tablet regimen of Truvada/TMC278 on 23 November

Merge Healthcare claims its capabilities extend across all stages of clinical trials, international studies, and many clinical specialty trials. In addition to the customizable myEDC platform, the Merge

The Phase I trial will be followed by a Phase IIa trial for the seasonal trivalent vaccine with the recommended H1N1, H3N2 and B influenza strains, which the

Although GeoVax is currently being tested clinically for HIV prevention, this is the first clinical trial in which the same products are being used for treatment of persons

Kinaxo’s acquisition establishes Evotec‘s as an integrated drug discovery and early development partner for pharma and biotechnology companies. Kinaxo’s novel technologies are expected to help Evotec arrive at

APF530 is indicated for the prevention of chemotherapy-induced nausea and vomiting. AP Pharma is in the process of preparing a resubmission responsive to the deficiencies listed in the

The results showed a record viable cell density of 242 million cells per ml at day 15, and a record titer achievement for a Fc-fusion protein of 11.5g

Circassia said PAP-1, a novel topical therapeutic for psoriasis and atopic dermatitis, is a highly specific immunosuppressant and a selective Kv1.3 inhibitor that has ideal topical delivery characteristics.